~~<i id='F0A1EF6BD0'><strike id='F0A1EF6BD0'><tt id='F0A1EF6BD0'><pre id='F0A1EF6BD0'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

author：Wikipedia 2025-10-06 12:10:27 Page View：6561

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Readout Newsletter: WuXi and Congress, Boundless Bio, etc.
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Abortion pill Supreme Court ruling could impact entire drug industry

AnnaMoneymaker/GettyImagesWASHINGTON—TheSupremeCourtonTuesdaywillhearopeningargumentsinanabortionmed

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Why the world’s most expensive drug might be worth the price

AdobeThestaffoftheInstituteforClinicalandEconomicReview,orICER,areknownasthenerdsofthedrugindustry:b